XSPRAY — Xspray Pharma publ AB Share News
0.000.00%
Last trade - 00:00- SEK631.98m
- SEK659.11m
Brief: Xspray Pharma, Bristol Myers Squibb Reach Settlement On Dasynoc Patent Litigation
Brief: Xspray Q2 Adj. EPS at SEK -2.27
Brief: Xspray Pharma Receives Request For Additional Information Concerning Dasynoc From FDA
Brief: XSpray BOD Resolves On Previously Announced Rights Issue
Brief: Xspray Reports Loss Before Tax of SEK 34.827 Million
Brief: Xspray Pharma Q1 Loss Before Tax Widens To SEK 34,8 Mln
Brief: US Court Denies 'Motion To Dismiss' From Xspray Pharma In Patent Dispute
Brief: XSpray Pharma Board Member Anders Bladh Acquires Shares From CEO
Brief: Xspray Pharma Partners With Eversana
Brief: Xspray Posts Q4 Adj. EPS Loss of SEK 2.48
Brief: Xspray Pharma's Drug Candidate XS004 Gets Granted Orphan Drug For Treatment Of Acute Lymphoblastic Leukemia
Brief: XSpray Pharma Q3 Loss Before Tax Widens To SEK 28.7 Mln
Brief: Xspray Pharma Q2 Loss Before Tax Narrows To SEK 28.9 Mln
Brief: XSpray Pharma: Dasynoc Granted Orphan Drug Designation In US
Brief: Xspray Pharma Q1 Pretax Loss Widens At SEK 18.9 Mln
Brief: Xspray Pharma Q1 Pretax Loss Widens To SEK 18.9 Mln
Brief: Xspray Pharma Q4 Loss Before Tax Widens To SEK 51.9 Mln
Brief: Xspray Pharma Completes Share Issue Of About SEK 100 Mln
Brief: XSpray Pharma Q3 Pre-Tax Loss At SEK 13.9 Mln